InflaRx N.V. (IFRX) Key Metrics
IFRX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · eurosIFRX returns How much profit the business earns on the capital it uses.
IFRX financial health Debt, liquidity and how easily interest is covered.
IFRX efficiency & capital use Working capital cycle and where the cash goes.
IFRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IFRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IFRX key metrics in euros
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −88.6% | −56.2% | −44.7% | −30.5% | −49.8% | −36.7% | −41.2% | −22.0% | −51.7% | — |
| Return on invested capital (ROIC) | — | −62.0% | −71.3% | −163.3% | −365.5% | — | — | — | — | — |
| Return on assets (ROA) | −69.6% | −47.0% | −38.3% | −25.9% | −42.8% | −32.4% | −37.9% | −21.0% | −31.5% | −54.0% |
| Return on tangible assets | −82.7% | −60.6% | −35.5% | −28.8% | −36.5% | −38.7% | −44.0% | −18.8% | −19.5% | −30.3% |
| Financial health | ||||||||||
| Total debt | €897,532 | €805,086 | €1.1M | €1.4M | €1.4M | €559,041 | €845,953 | €0 | €287,000 | €53.4M |
| Cash & short-term investments | €46.4M | €18.4M | €12.8M | €81.8M | €83.4M | €81.1M | €115.5M | €156.6M | €123.3M | €29.1M |
| Net debt | −€45.5M | −€17.6M | −€11.6M | −€80.5M | −€82.0M | −€80.6M | −€114.6M | −€156.6M | −€123.0M | €24.3M |
| Debt / equity | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | — |
| Debt / assets | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 1.81 |
| Current ratio | 4.13 | 5.06 | 6.50 | 7.48 | 5.10 | 8.54 | 8.46 | 20.39 | 26.01 | 16.83 |
| Quick ratio | 4.13 | 4.57 | 5.82 | 7.48 | 5.10 | 8.54 | 8.46 | 20.39 | 25.90 | 16.81 |
| Interest coverage | — | — | — | -712.4 | — | — | — | — | -8.7 | -3.8 |
| Working capital | €40.6M | €57.5M | €92.6M | €84.4M | €76.9M | €76.2M | €104.9M | €150.4M | €119.2M | €27.6M |
| Invested capital | −€4.0M | €43.8M | €90.9M | €7.9M | €23.3M | −€2.7M | −€7.5M | −€5.2M | −€3.6M | −€1.4M |
| Tangible asset value | €41.5M | €61.4M | €102.5M | €88.2M | €105.0M | €77.5M | €106.7M | €151.2M | €119.4M | −€25.7M |
| Net current asset value | €40.0M | €57.1M | €91.8M | €83.4M | €75.8M | €75.9M | €104.6M | €150.3M | €119.2M | −€25.8M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | €0 | €0 | €0 |
| Share buybacks (net) | — | — | — | — | — | — | €0 | €0 | €0 | €0 |
| Capex / revenue | 378.9% | 28.3% | 128.5% | — | — | — | — | — | 64.5% | — |
| Capex / depreciation | 0.26 | 0.10 | 0.14 | 0.27 | 0.06 | 0.13 | 0.90 | 4.64 | 2.10 | 1.61 |
| Stock-based compensation / revenue | 15,153.4% | 2,452.4% | 5,412.2% | — | — | — | — | — | 1,969.7% | — |
| R&D / revenue | 87,691.5% | 21,330.7% | 65,025.8% | — | — | — | — | — | 6,240.3% | — |
| SG&A / revenue | 52,908.3% | 9,219.7% | 22,533.9% | — | — | — | — | — | 2,224.2% | — |
| Efficiency | ||||||||||
| Days sales outstanding | 19,681.4 | 6,084.0 | 15,110.7 | — | — | — | — | — | 268.6 | — |
| Days of inventory on hand | — | 1,004.9 | 3,897.8 | — | — | — | — | — | 1,464.0 | 302.0 |
| Days payables outstanding | 221.2 | 468.5 | 3,459.7 | 1,942.2 | 790.3 | 3,179.5 | 4,689.1 | 11,302.8 | 16,413.5 | 9,744.8 |
| Cash conversion cycle (days) | 19,633.4 | 6,620.4 | 15,548.7 | — | — | — | — | — | -14,680.9 | — |
| Receivables turnover | 0.02 | 0.06 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | — | 1.36 | 0.00 |
| Payables turnover | 1.65 | 0.78 | 0.11 | 0.19 | 0.46 | 0.11 | 0.08 | 0.03 | 0.02 | 0.04 |
| Inventory turnover | — | 0.36 | 0.09 | — | — | — | — | — | 0.25 | 1.21 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | €1.6M | €2.8M | €2.6M | €1.4M | €1.4M | €1.3M | €1.1M | — | €170,000 | €174,000 |
| Average payables | €4.4M | €4.3M | €5.0M | €3.3M | €1.7M | €7.1M | €9.5M | €5.6M | €3.0M | €952,000 |
| Average inventory | €3.4M | €9.1M | €5.7M | €0 | — | — | — | €252,000 | €267,500 | €29,500 |
| Intangibles / total assets | 0.1% | 0.0% | 0.0% | 0.1% | 0.2% | 0.4% | 0.4% | 0.1% | 0.0% | 0.0% |
Computed from IFRX's annual financial statements (latest annual report filed March 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in euros; data from EODHD. Averages use the opening and closing balance of each year.
IFRX valuation and financial ratios
InflaRx earned a return on equity of −88.6% in fiscal 2025. It ended the year with €0.9 million of debt and €46.4 million in cash and short-term investments, a net cash position of €45.5 million.
See the IFRX income statement, the IFRX chart for price history, or the IFRX stock overview for the latest quote and news.
IFRX key metrics FAQ
What is InflaRx's return on equity?
InflaRx's return on equity (ROE) was −88.6% in fiscal 2025: net income of -€45.6 million on average shareholders' equity of €51.5 million.
How much debt does InflaRx have?
InflaRx had total debt of €0.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is InflaRx's current ratio?
InflaRx's current ratio was 4.13 at the end of fiscal 2025: current assets were 4.13 times current liabilities.